Skip to main content

Market Overview

Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vaccine Candidate

Share:

Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-19 vaccine.

  • The vaccine is currently in preclinical development and was invented at the Julius-Maximilians-University in Wuerzburg.
  • Additionally, the Company has entered into a research agreement with the University to conduct supplementary research activities and preclinical development studies on the potential vaccine.
  • The vaccine technology uses the approved typhoid fever vaccine Salmonella Typhi Ty21a as a carrier strain. It has the potential to be an orally active, live-attenuated bacterial vaccine to prevent COVID-19 infection.
  • The Company will pay an up-front payment of €140,000, certain milestones payments, sales milestones, and a percentage of any sub-licensing revenue.
  • Recently, AEZS obtained an exclusive license from The University of Sheffield, the U.K., to parathyroid hormone fusion polypeptides, which will initially be studied for primary hypoparathyroidism.
  • Price Action: AEZS shares increased 15.3% at $1.36 in premarket trading on the last check Monday.
 

Related Articles (AEZS)

View Comments and Join the Discussion!

Posted-In: COVID-19 VaccineBiotech News Penny Stocks Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com